anti-MMP9 monoclonal antibody

An anti-MMP9 monoclonal antibody is a therapeutic agent designed to selectively target and inhibit Matrix Metalloproteinase 9 (MMP9), a zinc-dependent endopeptidase involved in extracellular matrix degradation, tissue remodeling, and inflammatory processes. MMP9 is implicated in the pathogenesis of various diseases, including inflammatory bowel diseases (such as ulcerative colitis and Crohn's disease) and several cancers (such as gastric, colorectal, and pancreatic cancers), where it promotes tumor invasion, angiogenesis, and metastasis. By selectively binding to MMP9, these monoclonal antibodies aim to block its proteolytic activity, thereby preserving tissue barrier integrity and inhibiting pro-tumorigenic pathways. The most prominent clinical-stage candidate in this class has been andecaliximab (GS-5745), developed by Gilead Sciences, which underwent clinical evaluation for ulcerative colitis, Crohn's disease, and gastric cancer, though several of these trials were terminated due to insufficient efficacy. In 2024, andecaliximab was licensed by Ashibio, which is currently developing it for bone and connective tissue disorders, including fibrodysplasia ossificans progressiva (FOP) and spinal cord injury-induced heterotopic ossification.

Other names

MMP-9 inhibitor antibodyMMP9 inhibitor antibodyMMP 9 inhibitor antibodyanti-MMP-9 antibodyanti-MMP9 antibodyanti-MMP 9 antibodyanti-MMP-9 monoclonal antibodyanti-MMP9 monoclonal antibodyanti-MMP 9 monoclonal antibody